Correlation Between JBG SMITH and Catalyst Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both JBG SMITH and Catalyst Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining JBG SMITH and Catalyst Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between JBG SMITH Properties and Catalyst Pharmaceuticals, you can compare the effects of market volatilities on JBG SMITH and Catalyst Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in JBG SMITH with a short position of Catalyst Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of JBG SMITH and Catalyst Pharmaceuticals.
Diversification Opportunities for JBG SMITH and Catalyst Pharmaceuticals
-0.39 | Correlation Coefficient |
Very good diversification
The 3 months correlation between JBG and Catalyst is -0.39. Overlapping area represents the amount of risk that can be diversified away by holding JBG SMITH Properties and Catalyst Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Catalyst Pharmaceuticals and JBG SMITH is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on JBG SMITH Properties are associated (or correlated) with Catalyst Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Catalyst Pharmaceuticals has no effect on the direction of JBG SMITH i.e., JBG SMITH and Catalyst Pharmaceuticals go up and down completely randomly.
Pair Corralation between JBG SMITH and Catalyst Pharmaceuticals
Given the investment horizon of 90 days JBG SMITH Properties is expected to generate 0.82 times more return on investment than Catalyst Pharmaceuticals. However, JBG SMITH Properties is 1.22 times less risky than Catalyst Pharmaceuticals. It trades about 0.1 of its potential returns per unit of risk. Catalyst Pharmaceuticals is currently generating about -0.07 per unit of risk. If you would invest 1,565 in JBG SMITH Properties on September 13, 2024 and sell it today you would earn a total of 61.00 from holding JBG SMITH Properties or generate 3.9% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
JBG SMITH Properties vs. Catalyst Pharmaceuticals
Performance |
| Timeline |
| JBG SMITH Properties |
| Catalyst Pharmaceuticals |
JBG SMITH and Catalyst Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with JBG SMITH and Catalyst Pharmaceuticals
The main advantage of trading using opposite JBG SMITH and Catalyst Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if JBG SMITH position performs unexpectedly, Catalyst Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Pharmaceuticals will offset losses from the drop in Catalyst Pharmaceuticals' long position.| JBG SMITH vs. Cousins Properties Incorporated | JBG SMITH vs. Highwoods Properties | JBG SMITH vs. Douglas Emmett | JBG SMITH vs. Equity Commonwealth |
| Catalyst Pharmaceuticals vs. Day One Biopharmaceuticals | Catalyst Pharmaceuticals vs. Terns Pharmaceuticals | Catalyst Pharmaceuticals vs. X4 Pharmaceuticals | Catalyst Pharmaceuticals vs. Inozyme Pharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Complementary Tools
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |